RAC stock refers to the publicly traded shares of Race Oncology Limited, an Australian clinical-stage biopharmaceutical company listed on the Australian Securities Exchange under the ticker symbol RAC. The enterprise centers its corporate operations on advancing novel cancer therapies, specifically developing proprietary formulations and exploring targeted clinical pathways for its lead drug candidate, bisantrene, to address unmet medical needs in high-mortality oncological indications.